Management

This page includes content on healthcare management, including health system, hospital, department and clinic business management and administration. Areas of focus are on cardiology and radiology department business administration. Subcategories covered in this section include healthcare economics, reimbursement, leadership, mergers and acquisitions, policy and regulations, practice management, quality, staffing, and supply chain.

Cardiovascular Logistics (CVL), a private equity-backed cardiovascular platform with a roster of more than 150 cardiologist partners, has announced four new additions to its leadership team.

Private equity-backed cardiology management group expands its leadership team

Three of the new hires previously worked with Cardiovascular Institute of the South, the cardiology practice that launched Cardiovascular Logistics in 2023 with Lee Equity Partners.

Video - Ken Rosenfield, MD, MGH, and William Gray, MD, Lankenau Heart, explain impact of new CMS coverage for carotid stenting.

How a big CMS update on carotid stenting could impact interventional cardiology

Ken Rosenfield, MD, of Massachusetts General Hospital, and William Gray, MD, of Lankenau Heart Institute, detailed the long-term impact of a key policy shift. 

Kate Hanneman, MD, University Of Toronto, explains why vendors and hospitals are increasingly discussing lowing their carbon footprint by starting with radiology. 

What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Money court lawsuit judge ruling scales of justice

Healthcare fraud: DOJ recovered $1.9B in 2023, including several key settlements related to cardiology

The Department of Justice spent a substantial amount of time and energy targeting healthcare fraud in 2023, according to a new 80-page report. Some of the year's biggest settlements involved cardiac surgery and cardiac imaging. 

Boston Scientific has received U.S. Food and Drug Administration (FDA) approval for its Agent Drug-Coated Balloon (DCB) for the treatment of coronary in-stent restenosis (ISR) in patients with coronary artery disease.

FDA approves Boston Scientific’s new drug-coated balloon for coronary in-stent restenosis

Interventional cardiologists have been anticipating this news for quite some time. The device, the first of its kind, provides an alternative treatment option to repeat PCI or cardiac surgery for patients with coronary ISR.

Nauman Mushtaq, MD, Northwestern Medicine, explains the value of CT coronary calcium scoring for patients and for the cardiology business model.

The many benefits of using low-cost CT coronary calcium scoring to screen patients

CT calcium scoring provides valuable evaluations of intermediate-risk patients in addition to making good business sense for hospitals. Nauman Mushtaq, MD, an interventional cardiologist with Northwestern, shared his own experience with this technology. 

Biosense Webster gained CE mark approval for its Varipulse pulsed field ablation (PFA) system in Europe

Biosense Webster gains CE mark approval for new PFA system

The news represents yet another big regulatory approval for PFA technology in 2024. Could FDA approval be next for Biosense Webster?

Left, the FIRE1 heart failure remote monitoring device that gets implanted into the IVC to measure fluid volume status. Right, the external belt monitoring device worn by the patient that can alert clinicians about status changes so interventions can be done before a patient requires a hospital admission. 

Early feasibility study for implantable heart failure monitor moves forward 

Startup vendor FIRE1 completed patient enrollment in its U.S. early feasibility study for a heart failure remote monitoring device that directly measures fluid volume inside the IVC.

Around the web

GE HealthCare said the price of iodine contrast increased by more than 200% between 2017 to 2023. Will new Chinese tariffs drive costs even higher?

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.